Literature DB >> 8967763

Linear scleroderma and intractable epilepsy: neuropathologic evidence for a chronic inflammatory process.

G Pupillo, F Andermann, F Dubeau.   

Abstract

Entities:  

Mesh:

Year:  1996        PMID: 8967763     DOI: 10.1002/ana.410390223

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  6 in total

1.  Longstanding epileptic encephalopathy and linear localized scleroderma: two distinct pathologic processes in an adolescent.

Authors:  Donato Rigante; Domenica Battaglia; Ilaria Contaldo; Ilaria La Torraca; Laura Avallone; Stefania Gaspari; Giulia Bersani; Achille Stabile
Journal:  Rheumatol Int       Date:  2008-02-16       Impact factor: 2.631

2.  A significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings.

Authors:  Yvonne E Chiu; Sheetal Vora; Eun-Kyung M Kwon; Mohit Maheshwari
Journal:  Pediatr Dermatol       Date:  2012 Nov-Dec       Impact factor: 1.588

3.  CNS imaging findings associated with Parry-Romberg syndrome and en coup de sabre: correlation to dermatologic and neurologic abnormalities.

Authors:  Derrick A Doolittle; Vance T Lehman; Kara M Schwartz; Lily C Wong-Kisiel; Julia S Lehman; Megha M Tollefson
Journal:  Neuroradiology       Date:  2014-10-11       Impact factor: 2.804

4.  Anti-GAD epileptic encephalopathy in a toddler with Parry-Romberg syndrome.

Authors:  Stefano Sotgiu; Alessandro Consolaro; Susanna Casellato; Francesc Graus; Paolo Picco
Journal:  Neurol Sci       Date:  2019-12-11       Impact factor: 3.307

5.  Neurologic involvement in scleroderma en coup de sabre.

Authors:  Tiago Nardi Amaral; João Francisco Marques Neto; Aline Tamires Lapa; Fernando Augusto Peres; Caio Rodrigues Guirau; Simone Appenzeller
Journal:  Autoimmune Dis       Date:  2012-01-27

Review 6.  Localized scleroderma: clinical spectrum and therapeutic update.

Authors:  Mariana Figueiroa Careta; Ricardo Romiti
Journal:  An Bras Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.